Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Exanta Risk Management Plan May Not Prevent Liver Injury, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Cardiovascular & Renal Drugs Advisory Committee should determine whether AstraZeneca's proposed risk management plan for Exanta addresses delayed toxicity after short-term treatment. FDA also raises concerns about aspects of Exanta's clinical trial design.

You may also be interested in...



AstraZeneca Exanta For Prevention Of Thromboembolism Goes To Cmte. In September

The company is also seeking an indication for longer term secondary prevention of venous thromboembolism. Phase III results show oral direct thrombin inhibitor is equal to or better than warfarin, without dose adjustment.

Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint

FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.

RiskMAP Guidance Includes Plans For A Website

FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel